NRx Logo
  • Our Company
  • Our Science
    • Therapeutic Areas
      • Corona Virus / COVID-19
      • Psychiatry
    • Compounds Under Investigation
      • NRX-100 / NRX-101
      • ZYESAMI® (aviptadil)
      • For Physicians – Right to Try
    • NRx Pipeline
  • Pipeline
  • News & Media
  • Resources & Patient Stories
  • Investor Relations
  • Presentation
  • Careers
  • Contact Us
  • Search

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jul 16, 2020 1:00am EDT

NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2/3 Trial of RLF-100 for Critical COVID-19

Jun 24, 2020 1:30am EDT

NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19

Jun 11, 2020 1:00am EDT

Relief Therapeutics and NeuroRx Expand Clinical Trial Evaluating RLF-100 in Critically Ill COVID-19 Patients with Respiratory Failure to Houston Methodist Hospital

Jun 08, 2020 1:00am EDT

Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to All Patients with Critical COVID-19 and Respiratory Failure

Jun 01, 2020 4:03pm EDT

Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF-100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress

May 14, 2020 1:00am EDT

Relief Therapeutics and NeuroRx Announce Final Manufacturing Validation of RLF-100 for Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress Syndrome

Mar 26, 2020 6:45am EDT

RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress

Mar 25, 2020 2:45pm EDT

NeuroRx to discuss investigational drug for COVID-19 related Acute Respiratory Distress at Solebury Trout Virtual Global Healthcare Conference on March 26, 2020

Feb 10, 2020 8:13am EST

NeuroRx: Phase 3 Drug for Suicidal Bipolar Depression to Present at BIO CEO Conference

Jan 08, 2020 8:14am EST

NeuroRx Drug for Suicidal Bipolar Depression Receives Notification of Patent Allowance

  • arrow_back
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
NRx
  • Home
  • Our Company
  • Our Science
  • Pipeline
  • News & Media
  • Resources & Patient Stories
  • Investor Relations
  • Careers
  • Contact Us
  • NRx on Facebook
  • NRx on Twitter
  • NRx on Linkedin
  • Forward Looking Statement
  • Privacy Policy
  • Terms of Use
  • © 2022 NRx Pharmaceuticals, Inc.

  • NRx on Facebook
  • NRx on Twitter
  • NRx on Linkedin